NCT07090278View on ClinicalTrials.gov

Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

CompletedOBSERVATIONAL
Enrollment

2,734

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

October 31, 2024

Study Completion Date

November 30, 2024

Conditions
Sepsis-Associated Encephalopathy
Interventions
DRUG

ulinastatin

Ulinastatin for the treatment of sepsis patients during ICU stay

Trial Locations (1)

430030

Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Shusheng Li

OTHER

NCT07090278 - Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy | Biotech Hunter | Biotech Hunter